Vasogen to Present at BIO CEO & Investor Conference

Toronto, Ontario - February 07, 2006

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the BIO CEO & Investor Conference at The Waldorf Astoria Hotel at 12:00 p.m. Eastern Time on Wednesday, February 15, 2006, in New York.

A live audio web cast of the presentation can be accessed through Vasogen’s Web site at: www.vasogen.com. An archived replay will be available following the presentation.

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company is currently in the final stages of completing two pivotal phase III programs targeting large cardiovascular markets. The 2,400-patient phase III ACCLAIM trial is a 176-center international study designed to further investigate the use of Celacade™ technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure. The 550-patient phase III SIMPADICO trial, which was closed out early, is a 50-center North American study designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. These phase III programs are designed to support regulatory approval in North America and commercialization in North America and Europe. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs.

---